title: Sexual function in young women with spontaneous 46,XX primary ovarian insufficiency.
abstract: OBJECTIVE
  To assess sexual function in women with spontaneous 46,XX primary ovarian insufficiency after at least 3 months of a standardized hormone replacement regimen.
  
  
  METHODS
  Cross-sectional cohort, controlled.
  
  
  METHODS
  National Institutes of Health Clinical Research Center.
  
  
  METHODS
  Women with primary ovarian insufficiency (n = 143) and regularly menstruating controls (n = 70).
  
  
  METHODS
  Self-administered questionnaires, 100 microg/day E(2) patch, oral medroxyprogesterone acetate 10 mg for 12 days each month for patients.
  
  
  METHODS
  Derogatis Interview for Sexual Function Self-Report (DISF-SR).
  
  
  RESULTS
  Women with primary ovarian insufficiency had significantly lower DISF-SR composite scores compared with control women. Their serum total testosterone levels were significantly correlated with DISF-SR composite score, although this accounted for only 4% of the variance in this measure. Patients with testosterone levels below normal tended to have lower DISF-SR composite scores. Of patients with primary ovarian insufficiency, 9 of 127 (7%) scored below the second percentile on the composite sexual function score, compared with 1 of 49 control women (2%).
  
  
  CONCLUSIONS
  As assessed by the DISF-SR, sexual function is in the normal range for most young women with 46,XX spontaneous primary ovarian insufficiency who are receiving physiologic E(2) replacement. However, as a group, these young women score significantly lower on this sexual function scale than control women.
authors.affiliation: Integrative Reproductive Medicine Unit, Reproductive Biology and Medicine Branch, Intramural Research Program, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Sophia N
authors.initials: SN
authors.lastname: Kalantaridou
authors.forename: Vien H
authors.initials: VH
authors.lastname: Vanderhoof
authors.forename: Karim A
authors.initials: KA
authors.lastname: Calis
authors.forename: Emily C
authors.initials: EC
authors.lastname: Corrigan
authors.forename: James F
authors.initials: JF
authors.lastname: Troendle
authors.forename: Lawrence M
authors.initials: LM
authors.lastname: Nelson
mesh_terms: D000279:Administration, Cutaneous; D000284:Administration, Oral; D000328:Adult; D003430:Cross-Sectional Studies; D004311:Double-Blind Method; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D023961:Gonadal Dysgenesis, 46,XX / Q000150:complications* / Q000235:genetics; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D016649:Primary Ovarian Insufficiency / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology; D011446:Prospective Studies; D012725:Sexual Behavior / Q000187:drug effects*; D012735:Sexual Dysfunction, Physiological / Q000235:genetics / Q000503:physiopathology / Q000517:prevention & control*; D011795:Surveys and Questionnaires; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004967:Estrogens; D013739:Testosterone; D017258:Medroxyprogesterone Acetate